Health Catalyst Appoints Simeon Kohl as CEO; Ben Albert Moves to Chief Business Officer
HCAT sits 71% above its 52-week low of $0.955 on light trading volume (0.4× avg).
Summary
Health Catalyst appointed Simeon Kohl as CEO effective September 14, 2026, replacing Ben Albert, who becomes Chief Business Officer. Kohl receives a $600,000 salary and 2.75 million RSUs under a new inducement plan.
Key Events · Executive and Board Changes · HCAT
-
CEO Transition Announced
Effective September 14, 2026, Simeon Kohl will take over as CEO, President, and Class III director, succeeding Ben Albert, who steps down from those roles and the board on September 13, 2026.
-
New CEO Compensation Package
Kohl's package includes a $600,000 base salary, a target bonus of 100% of salary, and a grant of 2,747,385 RSUs vesting over approximately three years.
-
Inducement Plan Adopted
The board adopted the 2026 Employment Inducement Incentive Plan, reserving 2,747,385 shares for equity awards without stockholder approval under Nasdaq Rule 5635(c)(4).
-
Outgoing CEO Retained
Ben Albert transitions to Chief Business Officer with a $415,000 salary and a 60% target bonus, continuing to vest his existing equity awards.
Analysis · HCAT · Technology
After a turbulent year marked by a $151.6 million net loss, a $122.5 million goodwill impairment, and the $147 million sale of its Vitalware unit, Health Catalyst is replacing its CEO. The board has tapped Simeon Kohl, who previously led Performant Healthcare through a $670 million sale to Machinify, signaling a push for operational discipline and a potential strategic pivot. Outgoing CEO Ben Albert will remain as Chief Business Officer, which softens the disruption but also raises questions about whether this is a true leadership change or a reshuffling. Kohl is receiving 2,747,385 RSUs — a substantial equity grant for a company with a market cap around $127 million — which aligns his interests with shareholders but also creates meaningful dilution over the vesting period.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.6% of the 1819 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCAT was trading at $1.63 on NASDAQ in the Technology sector, with a market capitalization of approximately $127.2M. The 52-week trading range was $0.96 to $3.62. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.